Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.
Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, MacFarland RT, Henson GW, Calandra G; AMD3100 HIV Study Group.
Hendrix CW, et al. Among authors: glesby mj.
J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62. doi: 10.1097/01.qai.0000137371.80695.ef.
J Acquir Immune Defic Syndr. 2004.
PMID: 15385732
Clinical Trial.